Trade names or approved names. Part III. Special cases. Clinical trials
- PMID: 4465771
- PMCID: PMC2495491
- DOI: 10.1136/pgmj.50.580.114
Trade names or approved names. Part III. Special cases. Clinical trials
Abstract
The choice of standard drugs to be used in clinical trials must be based on consideration of human absorption data, in vitro characteristics, possible interactions, comparative efficacy and safety, previous data regarding the standard in relation to the syndrome to be studied, and correlation of blood levels, effectiveness and safety.
Similar articles
-
Trade names or approved names. Part IV. The solution. Prescribing and the regulation of formulation.Postgrad Med J. 1974 Feb;50(580):125-9. doi: 10.1136/pgmj.50.580.125. Postgrad Med J. 1974. PMID: 4465774 Free PMC article.
-
Trade names or approved names. Point II. Points of view. The clinical pharmacologist.Postgrad Med J. 1974 Feb;50(580):93-5. doi: 10.1136/pgmj.50.580.93. Postgrad Med J. 1974. PMID: 4465784 Free PMC article.
-
Trade names or approved names. Part III. Special cases. The digoxin affair.Postgrad Med J. 1974 Feb;50(580):98-102. doi: 10.1136/pgmj.50.580.98. Postgrad Med J. 1974. PMID: 4465786 Free PMC article.
-
Selection of an oral erythromycin product.Am J Hosp Pharm. 1980 Sep;37(9):1199-205. Am J Hosp Pharm. 1980. PMID: 6998290 Review.
-
[Evaluation of the physiological availability of drug substances in capsules].Farmatsiia. 1975 Jan-Feb;24(1):78-82. Farmatsiia. 1975. PMID: 770209 Review. Russian. No abstract available.